Page last updated: 2024-12-07

ter 286

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

TER 286: a glutathione-based glutathione S-transferase-activated cytotoxin; TLK-286 is the ((R)-(-))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID74089841
MeSH IDM0279597

Synonyms (1)

Synonym
ter 286

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"We aimed to evaluate the safety and efficacy of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer."( Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Belt, RJ; Boccia, RV; Brown, GL; Burris, HA; Caldwell, DC; Edelman, MJ; Englund, CW; Fidias, PM; Huberman, MS; Jones, M; Keck, JG; Kolevska, T; Lynch, TJ; Melnyk, O; Meng, L; Mills, GM; Rabin, MS; Sequist, LV; Temel, JS, 2009
)
0.35
" This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer."( Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Bast, RC; Brown, GL; Jones, MR; Kavanagh, JJ; Levenback, CF; Meng, L; Moore, CL; Ramirez, PT; Wolf, JL, 2010
)
0.36
"Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian cancer."( Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Bast, RC; Brown, GL; Jones, MR; Kavanagh, JJ; Levenback, CF; Meng, L; Moore, CL; Ramirez, PT; Wolf, JL, 2010
)
0.36
"To evaluate the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (OC)."( Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Boccia, RV; Brown, GL; Burke, JJ; Edwards, RP; Finkler, NJ; Hall, JB; Jones, M; Keck, JG; Melnyk, O; Meng, L; Rankin, EM; Rose, PG; Runowicz, CD; Vergote, I, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (15.00)18.2507
2000's14 (70.00)29.6817
2010's3 (15.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (33.33%)5.53%
Reviews8 (38.10%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (28.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]